Pulmonology Advisor17h
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after a treatment-free interval.
Physician's Weekly20h
Using Targeted Interventions to Elevate QOL & Symptom Control in Plaque Psoriasis
Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...
Physician's Weekly20h
Addressing Acute Pain & Related Challenges: Will Recent FDA Approval of a Novel Non-Opioid Analgesic Be a Game Changer?
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...
The Manila Times46m
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...
European Medical Journal19h
Long-Acting Injectable HIV Therapy Shows Early Promise in Human Trials
First-in-human study evaluating a novel long-acting injectable antiretroviral therapy provides promising early results on its ...
Ophthalmology Advisor15h
Dual Agonist Sepetaprost Noninferior to Timolol in Lowering IOP in Glaucoma, OHT
Sepetaprost demonstrated noninferiority to timolol 0.5% in decreasing intraocular pressure for patients with glaucoma or ocular hypertension.